Biopharmaceutical Drug Royalty Stream Solver

Underwrite purchasing top-line commercial pharmaceutical patent royalty rights, receiving passive quarterly cash distributions insulated from drug manufacturing and R&D costs.

Principal Investment & Drug Sales

Capital Invested in Drug Royalty Rights ($ USD)

Commercial Drug Annual Net Sales ($ Millions - e.g. $850M)

Contractual Gross Royalty Rate (% - e.g. 4.5%)

Your Ownership Share of the Royalty Pool (% - e.g. 0.25%)

Quarterly Cash & Net Annual Yield

Quarterly Net Royalty Distribution Check

+$23,906 / quarter

Annual Cash-on-Cash Royalty Dividend Yield

+$95,625 / yr (38.25% Cash Yield)

FDA Patent Exclusivity Period

11 Years Remaining Exclusivity (Zero Manufacturing Opex)